公开(公告)号：US20170298132A1

公开(公告)日：2017-10-19

申请号：US15623572

申请日：2017-06-15

Applicant: INNATE PHARMA

Inventor： CECILE BONNAFOUS ,  HELENE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/3023 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N33/57426 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20240391999A1

公开(公告)日：2024-11-28

申请号：US18648579

申请日：2024-04-29

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20190248895A1

公开(公告)日：2019-08-15

申请号：US16343796

申请日：2017-10-19

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20210087270A1

公开(公告)日：2021-03-25

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20190127463A1

公开(公告)日：2019-05-02

申请号：US16240906

申请日：2019-01-07

Applicant: INNATE PHARMA

Inventor： CECILE BONNAFOUS ,  HELENE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.